Sahar Keshvari

Sahar Keshvari

Auto-generated profile, based on publicly available information

Sahar Keshvari

Mater Research Institute-UQ, Translational Research Institute, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SKSahar Keshvari
Sahar Keshvari
MCMelanie Caruso
Melanie Caruso
NTNgari Teakle
Ngari Teakle
LBLena Batoon
Lena Batoon
ASAnuj Sehgal
Anuj Sehgal
DHDavid A. Hume
David A. Hume
Homozygous mutation of the Csf1r locus (Csf1rko) in mice, rats and humans leads to multiple postnatal developmental abnormalities. To enable analysis of the mechanisms underlying the phenotypic impacts of Csf1r mutation, we bred a rat Csf1rko allele to the inbred dark agouti (DA) genetic background and to a Csf1r-mApple reporter transgene. The Csf1rko led to almost complete loss of embryonic macrophages and ablation of most adult tissue macrophage populations. We extended previous analysis of the Csf1rko phenotype to early postnatal development to reveal impacts on musculoskeletal development and proliferation and morphogenesis in multiple organs. Expression profiling of 3-week old wild-type (WT) and Csf1rko livers identified 2760 differentially expressed genes associated with the loss of macrophages, severe hypoplasia, delayed hepatocyte maturation, disrupted lipid metabolism and the IGF1/IGF binding protein system. Older Csf1rko rats developed severe hepatic steatosis. Consistent with the developmental delay in the liver Csf1rko rats had greatly-reduced circulating IGF1. Transfer of WT bone marrow (BM) cells at weaning without conditioning repopulated resident macrophages in all organs, including microglia in the brain, and reversed the mutant phenotypes enabling long term survival and fertility. WT BM transfer restored osteoclasts, eliminated osteopetrosis, restored bone marrow cellularity and architecture and reversed granulocytosis and B cell deficiency. Csf1rko rats had an elevated circulating CSF1 concentration which was rapidly reduced to WT levels following BM transfer. However, CD43hi non-classical monocytes, absent in the Csf1rko, were not rescued and bone marrow progenitors remained unresponsive to CSF1. The results demonstrate that the Csf1rko phenotype is autonomous to BM-derived cells and indicate that BM contains a progenitor of tissue macrophages distinct from hematopoietic stem cells. The model provides a unique system in which to define the pathways of development of resident tissue macrophages and their local and systemic roles in growth and organ maturation.

8 August 2019 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
KIKatharine Irvine
Katharine Irvine
MCMelanie Caruso
Melanie Caruso
MCMichelle Ferrari Cestari
Michelle Ferrari Cestari
GDGemma M. Davis
Gemma M. Davis
SKSahar Keshvari
Sahar Keshvari
DHDavid A. Hume
David A. Hume

29 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HSHaressh Sajiir
Haressh Sajiir
SKSahar Keshvari
Sahar Keshvari
KWKuan Yau Wong
Kuan Yau Wong
DBDanielle Borg
Danielle Borg
Frederik J. SteynFrederik J. Steyn
Frederik J. Steyn
SPSumaira Zia PhD
Sumaira Zia PhD
Metabolic dysfunction-associated steatohepatitis (MASH) is the most prevalent cause of liver disease worldwide, with a single approved therapeutic. Previous research has shown that interleukin-22 (IL-22) can suppress β-cell stress, reduce local islet inflammation, restore appropriate insulin production, reverse hyperglycemia, and ameliorate insulin resistance in preclinical models of diabetes. In clinical trials long-acting forms of IL-22 have led to increased proliferation in the skin and intestine, where the IL-22RA1 receptor is highly expressed. To maximise beneficial effects whilst reducing the risk of epithelial proliferation and cancer, we designed short-acting IL-22-bispecific biologic drugs that successfully targeted the liver and pancreas. Here we show 10-fold lower doses of these bispecific biologics exceed the beneficial effects of native IL-22 in multiple preclinical models of MASH, without off-target effects. Treatment restores glycemic control, markedly reduces hepatic steatosis, inflammation, and fibrogenesis. These short-acting IL-22-bispecific targeted biologics are a promising new therapeutic approach for MASH.

15 May 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DHDavid A Hume
David A Hume
MCMelanie Caruso
Melanie Caruso
SKSahar Keshvari
Sahar Keshvari
OPOmkar L. Patkar
Omkar L. Patkar
ASAnuj Sehgal
Anuj Sehgal
KIKatharine Irvine
Katharine Irvine
The laboratory rat continues to be the model of choice for many studies of physiology, behavior, and complex human diseases. Cells of the mononuclear phagocyte system (MPS; monocytes, macrophages, and dendritic cells) are abundant residents in every tissue in the body and regulate postnatal development, homeostasis, and innate and acquired immunity. Recruitment and proliferation of MPS cells is an essential component of both initiation and resolution of inflammation. The large majority of current knowledge of MPS biology is derived from studies of inbred mice, but advances in technology and resources have eliminated many of the advantages of the mouse as a model. In this article, we review the tools available and the current state of knowledge of development, homeostasis, regulation, and diversity within the MPS of the rat.

22 December 2017 in Islets
Verified
Journal Article
Open access
DBDanielle J. Borg
Danielle J. Borg
FYFelicia Y. T. Yap
Felicia Y. T. Yap
SKSahar Keshvari
Sahar Keshvari
DSDavid G. Simmons
David G. Simmons
LGLinda Gallo
Linda Gallo
JFJosephine M Forbes
Josephine M Forbes
The contribution of environmental factors to pancreatic islet damage in type 1 diabetes remains poorly understood. In this study, we crossed mice susceptible to type 1 diabetes, where parental male (CD8+ T cells specific for IGRP206-214; NOD8.3) and female (NOD/ShiLt) mice were randomized to a diet either low or high in AGE content and maintained on this diet throughout pregnancy and lactation. After weaning, NOD8.3+ female offspring were identified and maintained on the same parental feeding regimen for until day 28 of life. A low AGE diet, from conception to early postnatal life, decreased circulating AGE concentrations in the female offspring when compared to a high AGE diet. Insulin, proinsulin and glucagon secretion were greater in islets isolated from offspring in the low AGE diet group, which was akin to age matched non-diabetic C57BL/6 mice. Pancreatic islet expression of Ins2 gene was also higher in offspring from the low AGE diet group. Islet expression of glucagon, AGEs and the AGE receptor RAGE, were each reduced in low AGE fed offspring. Islet immune cell infiltration was also decreased in offspring exposed to a low AGE diet. Within pancreatic lymph nodes and spleen, the proportions of CD4+ and CD8+ T cells did not differ between groups. There were no significant changes in body weight, fasting glucose or glycemic hormones. This study demonstrates that reducing exposure to dietary AGEs throughout gestation, lactation and early postnatal life may benefit pancreatic islet secretion and immune infiltration in the type 1 diabetic susceptible mouse strain, NOD8.3.

22 March 2016 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YKYu-Hee Kim
Yu-Hee Kim
JBJohanna L. Barclay
Johanna L. Barclay
JHJingjing He
Jingjing He
XLXiao Luo
Xiao Luo
HOHayley O'Neill
Hayley O'Neill
JWJonathan P. Whitehead
Jonathan P. Whitehead
Adipose tissue expansion occurs through a combination of hypertrophy of existing adipocytes and generation of new adipocytes via the process of hyperplasia, which involves the proliferation and subsequent differentiation of preadipocytes. Deficiencies in hyperplasia contribute to adipose tissue dysfunction and the association of obesity with chronic cardiometabolic diseases. Thus, increased understanding of hyperplastic pathways may be expected to afford novel therapeutic strategies. We have reported that fibroblast growth factor (FGF)‐1 promotes proliferation and differentiation of human preadipocytes and recently demonstrated that bone morphogenetic protein and activin membrane‐bound inhibitor (BAMBI) is a central, proximal effector. Herein, we describe the identification and characterization of carboxypeptidase X (CPX)‐1, a secreted collagen‐binding glycoprotein, as a novel downstream effector in human primary and Simpson‐Golabi‐Behmel syndrome preadipocytes. CPX‐1 expression increased after treatment of preadipocytes with FGF‐1, BAMBI knockdown, or induction of differentiation. CPX‐1 knockdown compromised preadipocyte differentiation coincident with reduced collagen expression. Furthermore, preadipocytes differentiated on matrix derived from CPX‐1 knockdown cells exhibited reduced Glut4 expression and insulin‐stimulated glucose uptake. Finally, CPX‐1 expression was increased in adipose tissue from obese mice and humans. Collectively, these findings establish CPX‐1 as a positive regulator of adipogenesis situated downstream of FGF‐1/BAMBI that may contribute to hyperplastic adipose tissue expansion via affecting extracellular matrix remodeling.— Kim, Y.‐H., Barclay, J. L., He, J., Luo, X., O'Neill, H. M., Keshvari, S., Webster, J. A., Ng, C., Hutley, L. J., Prins, J. B., Whitehead, J. P. Identification of carboxypeptidase X (CPX)‐1 as a positive regulator of adipogenesis. FASEB J. 30, 2528‐2540 (2016). www.fasebj.org